Richard C. Zink is a Principal Research Statistician Developer in the JMP Life Sciences division at SAS Institute. He is a developer for JMP Clinical, an innovative software package designed to streamline the review of clinical trial data. He joined SAS in 2011 after eight years in the pharmaceutical industry, where he designed and analyzed clinical trials for patients diagnosed with chronic hepatitis B infection, chronic myeloid leukemia, glaucoma, dry eye disease, blepharitis, or cystic fibrosis; he also participated in US and European drug submissions and in two FDA advisory committee hearings. When not actively engaged in clinical development responsibilities, he supported non-clinical development, pharmaceutical sciences, and sales and marketing activities. Richard is a member of the Biopharmaceutical Section of the American Statistical Association, the Drug Information Association, and Statisticians in the Pharmaceutical Industry. He is currently the Statistics Section Editor for Therapeutic Innovation & Regulatory Science (formerly Drug Information Journal). His research interests include the analysis of pre- and post-market adverse events, subgroup identification for patients with enhanced treatment response, and risk-based monitoring and fraud detection in clinical trials. Richard holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill and has more than 20 years of SAS programming experience. This is his first book.